Evaluation of knowledge, attitude and practices about melanoma among pharmacy students in private institute: A web based cross-sectional study

J. Abel Joe Jacob; S. Jayakumari

doi:10.53730/ijhs.v6nS1.7500

Authors

J. Abel Joe Jacob Pharm.D Intern, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai, Tamil Nadu, India
S. Jayakumari
hodpcognosy@velsuniv.ac.in
Head of Department, Department of Pharmacognosy, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai, Tamil Nadu, India

Keywords:

Melanoma, Pharmacy students, knowledge, Questionnaire

Abstract

Aim - To Evaluate and compare the Knowledge, Attitude & Practice about melanoma among pharmacy students in private institute.Material and Methods- The study is carried out with a sample size of 109 students in VISTAS, Pallavaram, at Chennai. It is a web based cross –sectional study. The data were collected by e-questionnaire of 25 questions into 4 domains, where demographic details and questions regarding knowledge, attitude and practice of Melanoma where asked among pharmacy students in Chennai. Results- In our study questionnaire was circulated to 109 pharmacy students totally, all 109 pharmacy students have responded giving response rate of (100%) who is studying in private institution at Chennai. The statistical analysis was calculated based on review performed the data were entered into Epidata 3.1 and exported to SPSS version 22 and analyzed using descriptive statistics and logistic regression.Conclusion- As per the study results the study participants have good knowledge, Attitudes and Practice towards melanoma. Most of our study participants were aware about melanoma, risk factors, causes and symptoms of melanoma. Both M.Pharm and pharm D have GOOD knowledge, Attitude, and practice. Compared to M.Pharm, pharm D have much better knowledge, Attitude and Practice.

Downloads

Download data is not yet available.

References

Garbe C, Leiter U. Melanoma epidemiology and trends. ClinDermatol. 2009;27(1):3–9. [PubMed] [Google Scholar].

Australian Institute of Health and Welfare Cancer in Australia 2017, Cancer series no.101, Cat. no. CAN 100. Canberra: AIHW; 2017. [Google Scholar]

Whiteman D, Green A, Olsen C. The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031. J Invest Dermatol. 2016;136(6):1161–71. [PubMed] [Google Scholar]

Severi G, Giles G, Robertson C, Boyle P, Autier P. Mortality from cutaneous melanoma: evidence for contrasting trends between populations. Br J Cancer. 2000;82(11):1887–91. [PMC free article] [PubMed] [Google Scholar]

Ghazawi F, Cyr J, Darwich R, Le M, Rahme E, Moreau L, et al. Cutaneous malignant melanoma incidence and mortality trends in Canada: A comprehensive population-based study. J Am AcadDermatol. 2019;80(2):448–59. [PubMed] [Google Scholar]

Elliott T, Whiteman D, Olsen C, Gordon L. Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis. Appl Health Econ Health Policy. 2017;15(6):805–16. [PubMed] [Google Scholar]

Sera F,Gandini S Cattaruzza MS, Pasquini P, Picconi O, Boyle P and Melchi CF: Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 41: 45-60, 2015.

Elwood JM and Jopson J: Melanoma and sun exposure: an overview of published studies. Int J Cancer 73: 198-203, 1997.

Elwood JM, Gallagher RP, Worth AJ, Wood WS and Pearson JC: Etiological differences between subtypes of cutaneous malignant melanoma: Western Canada Melanoma Study. J Natl Cancer Inst 78: 37-44, 1987.

International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer: The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int J Cancer 120: 1116-1122, 2007.

Stern RS: The risk of melanoma in association with long-term exposure to PUVA. J Am AcadDermatol 44: 755-761, 2001.

Bevona C, Goggins W, Quinn T, Fullerton J and Tsao: Cutaneous melanomas associated with nevi. Arch Dermatol 139: 1620-1624, 2003.

Holly EA, Kelly JW, Shpall SN and Chiu SH: Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am AcadDermatol 17: 459-468, 1987.

Grob JJ, Gouvernet J, Aymar D, Mostaque A, Romano MH, Collet AM, Noe MC, Diconstanzo MP and Bonerandi JJ: Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 66: 387-395, 1990.

Halpern AC, Guerry D 4th, Elder DE, Clark WH Jr, Synnestvedt M, Norman S and Ayerle R: Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case–control study. Arch Dermatol 127: 995-999, 1991.

Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P and Melchi CF: Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41: 28-44, 2005.

Watt AJ, Kotsis SV and Chung KC: Risk of melanoma arising in large congenital melanocytic nevi: a systematic review. PlastReconstrSurg 113: 1968-1974, 2004.

Tannous ZS, Mihm MC Jr., Sober AJ and Duncan LM: Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am AcadDermatol 52: 197-203, 2005.

Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, Guerry D 4th and Clark WH Jr: Clinically recognized dysplastic nevi: a central risk factor for cutaneous melanoma. JAMA 277: 1439-1444, 1997.

Purdue MP, From L and Armstrong BK: Genes, Environment, and Melanoma Study Group. Etiologic and other factors predicting nevus associated cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 14: 2015-2022, 2005.